Book contents
- Frontmatter
- Contents
- Tables
- Figures
- About the Editors
- Contributors
- Preface
- Acknowledgments
- Foreword
- Introduction: Charting a Sustainable Path for the Twenty-First Century Pharmaceutical Industry
- PART I PROFITS, PATIENTS' RIGHTS, AND SCIENTIFIC PROGRESS: THE ETHICS OF CLINICAL RESEARCH CONDUCTED IN PRIVATE ENTERPRISES
- PART II MARKETING AND THE EFFICIENT UTILIZATION OF HEALTHCARE RESOURCES: ETHICAL AND PUBLIC POLICY CHALLENGES
- PART III PATENTS, PRICING, AND EQUAL ACCESS
- Introduction to Part III
- 15 Intellectual Property Rights, Access to Life-Enhancing Drugs, and Corporate Moral Responsibilities
- 16 A Future Agenda for Government–Industry Relations
- 17 AIDS Activism and the Pharmaceutical Industry
- 18 The Campaign Against Innovation
- 19 Third World Perspectives on Global Pharmaceutical Access
- 20 The Promise of Vaccines and the Influenza Vaccine Shortage of 2004: Public and Private Partnerships
- PART IV CONCLUDING THOUGHTS: CHARTING A SUSTAINABLE PATH FOR THE TWENTY-FIRST CENTURY
- Notes
- Index
17 - AIDS Activism and the Pharmaceutical Industry
Published online by Cambridge University Press: 04 December 2009
- Frontmatter
- Contents
- Tables
- Figures
- About the Editors
- Contributors
- Preface
- Acknowledgments
- Foreword
- Introduction: Charting a Sustainable Path for the Twenty-First Century Pharmaceutical Industry
- PART I PROFITS, PATIENTS' RIGHTS, AND SCIENTIFIC PROGRESS: THE ETHICS OF CLINICAL RESEARCH CONDUCTED IN PRIVATE ENTERPRISES
- PART II MARKETING AND THE EFFICIENT UTILIZATION OF HEALTHCARE RESOURCES: ETHICAL AND PUBLIC POLICY CHALLENGES
- PART III PATENTS, PRICING, AND EQUAL ACCESS
- Introduction to Part III
- 15 Intellectual Property Rights, Access to Life-Enhancing Drugs, and Corporate Moral Responsibilities
- 16 A Future Agenda for Government–Industry Relations
- 17 AIDS Activism and the Pharmaceutical Industry
- 18 The Campaign Against Innovation
- 19 Third World Perspectives on Global Pharmaceutical Access
- 20 The Promise of Vaccines and the Influenza Vaccine Shortage of 2004: Public and Private Partnerships
- PART IV CONCLUDING THOUGHTS: CHARTING A SUSTAINABLE PATH FOR THE TWENTY-FIRST CENTURY
- Notes
- Index
Summary
The AIDS epidemic is widely recognized as a turning point in the relations between the people directly affected by a disease and the many groups, agencies, and institutions that respond to the disease. People with AIDS and their advocates are credited with spearheading several fundamental changes in how society and its institutions behave when confronting a new, life-threatening illness. Some of these changes include:
Reforms in the way new drugs are approved by the U.S. Food and Drug Administration;
Greatly enhanced communication between patients and their physicians;
A new emphasis on patient empowerment in all aspects of the healthcare system;
New inclusion of patients and advocates in scientific decision-making and the conduct of clinical research;
Greater involvement of the public at every level in the management of research at the National Institutes of Health;
More political oversight of how research is funded by taxpayers and how research dollars are divided between disease interest groups;
An unprecedented degree of interaction between patients, their advocates, and the pharmaceutical industry in the development, testing, pricing, and marketing of new therapies.
Given today's increasing concerns about the cost of healthcare, and the public's demand for ever better solutions to medical problems, this chapter will focus on the last item on the list, the dramatic changes that have occurred in how a patient community interacts with the pharmaceutical industry. Although the pharmaceutical industry has long maintained significant relations with the public and with various disease-interest, nonprofit foundations, there is little precedent for the ways in which companies now interact routinely with AIDS groups.
- Type
- Chapter
- Information
- Ethics and the Pharmaceutical Industry , pp. 300 - 325Publisher: Cambridge University PressPrint publication year: 2005
- 2
- Cited by